PMID- 35317523
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220324
IS  - 2372-7705 (Print)
IS  - 2372-7705 (Electronic)
IS  - 2372-7705 (Linking)
VI  - 24
DP  - 2022 Mar 17
TI  - Promoting role of pentraxin-3 in esophageal squamous cell carcinoma.
PG  - 772-787
LID - 10.1016/j.omto.2022.02.005 [doi]
AB  - Pentraxin 3 (PTX3) is an inflammatory molecule that is closely related to the 
      proliferation, invasion, and metastasis of cancer. In order to explore the role 
      of PTX3 in the occurrence and development of esophageal carcinoma (ESCA), we 
      modified the PTX3 gene in ESCA cell lines to obtain the model of gene knockout 
      and overexpression and studied cell proliferation, cycle, apoptosis, migration 
      ability, energy metabolism, and sensitivity to chemotherapy and radiotherapy. We 
      observed the increase in cell proliferation, cycle, apoptosis, migration ability, 
      and sensitivity to chemotherapy and radiotherapy in the PTX3 knockout model, 
      while in the PTX3 overexpression model, these phenomena were significantly 
      reduced. Knockout of the PTX3 also resulted in decreased cell glycolysis and 
      increased oxidative phosphorylation, which is consistent with other findings that 
      PTX3 affects the tumorigenic ability of cells and their sensitivity to docetaxel. 
      In ESCA, SOX9 directly regulates the expression of PTX3, while human leukocyte 
      antigen (HLA)-system-related genes are significantly up-regulated when lacking 
      PTX3. These results indicate that SOX9 may play a crucial role in regulating PTX3 
      and affecting the HLA system in ESCA.
CI  - (c) 2022.
FAU - Fan, Zhirui
AU  - Fan Z
AD  - Department of Chinese and Western Integrative Medicine, the First Affiliated 
      Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China.
FAU - Zheng, Yuanyuan
AU  - Zheng Y
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan, China.
AD  - Internet Medical and System Applications of National Engineering Laboratory, the 
      First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, 
      China.
FAU - Li, Xiaoli
AU  - Li X
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan, China.
FAU - Deng, Xiaoming
AU  - Deng X
AD  - Department of Chinese and Western Integrative Medicine, the First Affiliated 
      Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China.
FAU - Ba, Yan
AU  - Ba Y
AD  - Department of Chinese and Western Integrative Medicine, the First Affiliated 
      Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China.
FAU - Feng, Kun
AU  - Feng K
AD  - Department of Chinese and Western Integrative Medicine, the First Affiliated 
      Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China.
FAU - Su, Jin
AU  - Su J
AD  - Department of Chinese and Western Integrative Medicine, the First Affiliated 
      Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China.
FAU - Wang, Hui
AU  - Wang H
AD  - Department of Chinese and Western Integrative Medicine, the First Affiliated 
      Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China.
FAU - Suo, Zhenhe
AU  - Suo Z
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan, China.
AD  - Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, 
      Institute of Clinical Medicine, University of Oslo, 999026 Montebello, Oslo, 
      Norway.
FAU - Li, Lifeng
AU  - Li L
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan, China.
AD  - Internet Medical and System Applications of National Engineering Laboratory, the 
      First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20220214
PL  - United States
TA  - Mol Ther Oncolytics
JT  - Molecular therapy oncolytics
JID - 101666776
PMC - PMC8908267
OTO - NOTNLM
OT  - SOX9
OT  - esophageal squamous cell carcinoma (ESCC)
OT  - human leukocyte antigen (HLA)
OT  - immunity
OT  - inflammation
OT  - pentraxin 3 (PTX3)
COIS- The authors declare no competing interests.
EDAT- 2022/03/24 06:00
MHDA- 2022/03/24 06:01
PMCR- 2022/02/14
CRDT- 2022/03/23 05:15
PHST- 2021/06/15 00:00 [received]
PHST- 2022/02/03 00:00 [accepted]
PHST- 2022/03/23 05:15 [entrez]
PHST- 2022/03/24 06:00 [pubmed]
PHST- 2022/03/24 06:01 [medline]
PHST- 2022/02/14 00:00 [pmc-release]
AID - S2372-7705(22)00022-5 [pii]
AID - 10.1016/j.omto.2022.02.005 [doi]
PST - epublish
SO  - Mol Ther Oncolytics. 2022 Feb 14;24:772-787. doi: 10.1016/j.omto.2022.02.005. 
      eCollection 2022 Mar 17.